GlassScriptPhysician profile
Steven R Sacks
NPI 1326067935
$2,690.35
in general payments reported to CMS, 2019-2025
32 companies · $243 in 2025
The $243 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $145 · 2021: $407 · 2022: $577 · 2023: $309 · 2024: $690 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,241.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $447.89 | 2019-2025 | Stelara, Simponi, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $304.50 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $240.92 | 2019-2025 | Entyvio |
| Abbvie INC. | $187.11 | 2021-2025 | |
| Qol Medical, LLC | $162.69 | 2019-2024 | Sucraid, Sucraid |
| Evoke Pharma, INC. | $131.04 | 2020-2025 | Gimoti |
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| Celltrion USA INC. | $119.20 | 2024-2025 | Vegzelma |
| Lilly USA, LLC | $103.71 | 2021-2025 | Omvoh |
| Allergan, INC. | $98.00 | 2019-2020 | |
| Gilead Sciences, INC. | $82.87 | 2023-2024 | |
| Intercept Pharmaceuticals, INC. | $74.24 | 2019-2024 | Ocaliva |
| Pfizer INC. | $59.09 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $58.13 | 2024 | |
| Phadia US INC. | $57.69 | 2023-2024 | Immunocap |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $52.12 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $41.06 | 2024 | Voquezna |
| Redhill Biopharma INC. | $38.51 | 2020-2022 | |
| Amarin Pharma, INC. | $34.59 | 2020-2022 | |
| Celgene Corporation | $31.88 | 2021-2022 | |
| Madrigal Pharmaceuticals | $29.92 | 2025 | Rezdiffra |
| Ardelyx, INC. | $27.61 | 2024 | Ibsrela |
| Exact Sciences Corporation | $24.72 | 2023 | Cologuard Collection Kit |
| Medtronic, INC. | $21.85 | 2022 | |
| Amgen INC. | $21.03 | 2022 | |
| Mirum Pharmaceuticals, INC. | $20.13 | 2023 | Livmarli |
| Ucb, INC. | $17.66 | 2019 | |
| Eisai INC. | $17.12 | 2021 | |
| Novo Nordisk INC | $16.02 | 2020 | |
| Glaxosmithkline, LLC. | $15.41 | 2019 | |
| Braintree Laboratories, INC. | $14.99 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $13.65 | 2025 | Riteclip |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Sacks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.